High levels of topoisomerase IIα protein expression in diffuse large B-cell lymphoma are associated with high proliferation, germinal center immunophenotype, and response to treatment

References

• Kaufmann WK. Human topoisomerase II function, tyrosine phosphorylation and cell cycle checkpoints. Proc Soc Exp Biol Med 1998;217:327–334.
   PubMed Web of Science ®Google Scholar
• Liu LF. DNA topoisomerase poison as antitumour drugs. Ann Rev Biochem 1989;58:351–375.
   PubMed Web of Science ®Google Scholar
• Nitiss JL, Beck WT. Antitopoisomerase drug action and resistance. Eur J Cancer 1996;32A:958–966.
   PubMed Web of Science ®Google Scholar
• Walker JV, Nitiss JL. DNA topoisomerase II as a target for cancer chemotherapy. Cancer Invest 2002;20:570–589.
   PubMed Web of Science ®Google Scholar
• Bandele OJ, Osheroff N. The efficacy of topoisomerase II-targeted anticancer agents reflects the persistence of drug-induced cleavable complexes in cells. Biochemistry 2008;47:11900–11908.
   PubMed Web of Science ®Google Scholar
• Burgess DJ, Dole J, Zender L, et al Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc Natl Acad Sci USA 2008;105:9053–9058.
   PubMed Web of Science ®Google Scholar
• Holden JA, Perkins SL, Snow GW, Kjeldsberg CR. Immunohistochemical staining for DNA topoisomerase II in non-Hodgkin's lymphomas. Am J Clin Pathol 1995;104:54–59.
   PubMed Web of Science ®Google Scholar
• Nitiss JL. Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer 2009;9:338–350.
   PubMed Web of Science ®Google Scholar
• Beck WT, Danks MK, Wolverton JS, Kim R, Chen M. Drug resistance associated with altered DNA topoisomerase II. Adv Enzyme Regul 1993;33:113–127.
   PubMedGoogle Scholar
• Tanner M, Isola J, Wiklund T, et al topoisomerase IIA gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER2/neu amplified breast cancer. Results from the randomised trial SBG9401. J Clin Oncol 2006;24:2428–2438.
   PubMed Web of Science ®Google Scholar
• Olsen K, Knudsen H, Rasmussen B, et al Amplification of HER2 and TOP2A and deletion of TOP2A genes in breast cancer investigated by new FISH probes. Acta Oncol 2004;43:35–42.
   PubMed Web of Science ®Google Scholar
• Pileri SA, Dirnhofer S, Went P, et al Diffuse large B-cell lymphoma: one or more entities? Present controversies and possible tools for its subclassification. Histopathology 2002;41:482–509.
   PubMed Web of Science ®Google Scholar
• Alizadeh AA, Eisen MB, Davis RE, et al Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503–511.
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, et al Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2003;103:275–282.
   PubMed Web of Science ®Google Scholar
• Bai M, Skyrlas A, Agnantis NJ, et al Relationships between B-cell differentiation, apoptosis and proliferation in diffuse large B-cell lymphomas. Anticancer Res 2005;25:347–362.
   PubMed Web of Science ®Google Scholar
• Bai M, Agnantis NJ, Skyrlas A, et al Increased expression of the bcl6 and CD10 proteins is associated with increased apoptosis and proliferation in diffuse large B cell lymphomas. Mod Pathol 2003;16:471–480.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, et al Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–586.
   PubMed Web of Science ®Google Scholar
• Tanne M, Jarvineu P, Isola J, et al Amplification of HER-2/neu and topoisomerase II-α in primary and metastatic breast cancer. Cancer Res 2001;61:5345–5348.
   PubMed Web of Science ®Google Scholar
• Bai M, Vlahonikolis J, Agnantis NJ, et al Low expression of p27 protein combined with altered p53 and Rb/p16 expression status is associated with increased expression of cyclin A and cyclin B1 in diffuse large B cell lymphomas. Mod Pathol 2001;14:1105–1113.
   PubMed Web of Science ®Google Scholar
• Bai M, Tsanou E, Agnantis NJ, et al Expression of cyclin D3 and cyclin E and identification of distinct clusters of proliferative activity and apoptosis status in diffuse large B cell lymphomas. Histol Histopathol 2003;18:449–457.
   PubMed Web of Science ®Google Scholar
• Bai M, Tsanou E, Skyrlas A, Sainis I, Agnantis N, Kanavaros P. Alterations of the p53, Rb and p27 tumour suppressor pathways in diffuse large B-cell lymphomas. Anticancer Res 2007;27:2345–2352.
   PubMed Web of Science ®Google Scholar
• Scarlos DV, Bai M, Goussia A, et al Expression of a molecular marker panel as a prognostic tool in gastric cancer patients treated postoperatively with docetaxel and irinotecan. A study of the Hellenic Cooperative Oncology Group (HeCOG). Anticancer Res 2007;27:2973–2983.
   Google Scholar
• Mass R, Press M, Anderson S, et al Evaluation of clincal outcomes according to HER2 detection by FISH in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer 2005;6:240–246.
   PubMedGoogle Scholar
• Bhargava R, Lai P, Chen B. HER2/neu and topoisomerase IIA gene amplification and protein expession in invasive breast carcinomas: Chromogenic in situ hybridization and immunohistochemical analyses. Am J Clin Pathol 2005;123:889–895.
   PubMed Web of Science ®Google Scholar
• Gennari A, Sormani M, Pronzato P, et al HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomised trials. J Natl Cancer Inst 2008;100:14–20.
   PubMed Web of Science ®Google Scholar
• O'Malley FP, Chai S, Tu D, et al Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst 2009;101:644–650.
   PubMed Web of Science ®Google Scholar
• Mano MS, Rosa DD, De Azambuja E, Ismael GF, Durbecq V. The 17q12-q21 amplicon: HER2 and topoisomerase IIA and their importance to the biology of solid tumours. Cancer Treat Rev 2007;33:64–77.
   PubMed Web of Science ®Google Scholar
• Kim MA, Jung EJ, Lee HS, et al Evaluation of HER2 gene status in gastric carcinoma using immunohistochemistry, FISH and real-time quantitative polymerase chain reaction. Hum Pathol 2007;38:1386–1393.
   PubMed Web of Science ®Google Scholar
• Szvalb S, Stein M, Gershuny A, Gez E, Hadary A, Zidan J. Lack of HER2 gene amplification in non Hodgkin lymphoma using chromogenic in situ hybridisation test. Leuk Lymphoma 2009;50:736–740.
   PubMed Web of Science ®Google Scholar
• Provencio M, Corbacho C, Salas C, et al The topoisomerase IIA expression correlates with survival in patients with advanced Hodgkin's lymphoma. Clin Cancer Res 2003;9:1406–1411.
   PubMed Web of Science ®Google Scholar
• Lohri A, Reuter J, Gudat F, Herrmann R. Topoisomerase IIA mRNA and tumour cell proliferation in non-Hodgkin's lymphoma. J Clin Pathol 1997;50:22–26.
   PubMed Web of Science ®Google Scholar
• Doussis-Anagnostopoulou IA, Vassilakopoulos TP, Thymara I, et al topoisomerase IIA expression as an independent prognostic factor in Hodgkin's lymphoma. Clin Cancer Res 2008;14:1759–1766.
   PubMed Web of Science ®Google Scholar
• Korkolopoulou P, Angelopoulou M, Siakantari M, et al Evaluation of DNA topoisomerase IIA expression provides independent prognostic information in non-Hodgkin's lymphomas. Histopathology 2001;38:45–53.
   PubMed Web of Science ®Google Scholar
• Schrader C, Meusers P, Brittinger G, et al Topoisomerase IIA expression in mantle cell lymphoma: a marker of cell proliferation and a prognostic factor for clinical outcome. Leukemia 2004;18:1200–1206.
   PubMed Web of Science ®Google Scholar
• Wang YH, Takanashi M, Tsuji K, et al Level of DNA topoisomerase IIA mRNA predicts the treatment response of relapsed acute leukemic patients. Leuk Res 2009;33:902–907.
   PubMed Web of Science ®Google Scholar
• Stammler G, Sauerbrey A, Volm M. Determination of DNA topoisomerase II in newly diagnosed childhood acute lymphoblastic leukemia by immunocytochemistry and RT-PCR. Cancer Lett 1994;84:141–147.
   PubMed Web of Science ®Google Scholar
• Lodge AJ, Hall AG, Reid MM, et al Topoisomerase IIA and IIB expression in childhood acute lymphoblastic leukaemia: relation to prognostic factors and clinical outcome. J Clin Pathol 2001;54:31–36.
   PubMed Web of Science ®Google Scholar
• Oiu J, Catapano CV, Fernandes DJ. Formation of topoisomerase II alpha complexes with nascent DNA is related to VM-26-induced cytotoxicity. Biochemistry 1996;50:16354–16360.
   Google Scholar
• Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM. A gene-expression based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA 2003;19:9991–9996.
   Web of Science ®Google Scholar
• Davis RE, Brown KD, Siebenlist U, et al Constitutive NFkB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001;194:1861–1874.
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Chan WC, et al The use of molecular profiling to predict survival after chemotherapy for diffuse large B cell lymphoma. N Engl J Med 2002;346:1937–1947.
   PubMed Web of Science ®Google Scholar
• Ohsima K, Kawasaki C, Muta H, et al CD10 and BCL10 expression in DLBCL: CD10 is a marker of improved prognosis. Histopathology 2002;39:156–162.
   Web of Science ®Google Scholar
• Lossos IS, Jones CD, Warnke R, et al Expression of a single gene BCL6 strongly predicts survival in patients with DLBCL. Blood 2001;98:945–951.
   PubMed Web of Science ®Google Scholar